A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Sickle cell disease is a genetic red blood cell disorder characterized by vaso-occlusion from
sickling of red blood cells, that can lead to pain or organ complications such as acute chest
syndrome. Sickle cell disease is associated with low amounts of nitric oxide, a compound
important for dilating the blood vessel wall. Citrulline is a substance that is known to
increase nitric oxide. The goal of this Phase I study are to find the highest safe dose of
continuous IV citrulline that can be given to individuals with sickle cell disease
experiencing a sickle cell pain crisis or acute chest syndrome without causing severe side
effects.